A Pulmonary Trunk Banding Model of Pressure Overload Induced Right Ventricular Hypertrophy and Failure
November 29th, 2018
9.4K views
We present a surgical method to induce right ventricular hypertrophy and failure in rats.
Overview
This article presents a surgical method to induce right ventricular hypertrophy and failure in rats. The technique allows for a precise and reproducible increase in afterload, facilitating the study of right ventricular failure mechanisms and treatments.
Key Study Components
Area of Science
- Cardiovascular physiology
- Surgical techniques in animal models
- Right ventricular failure research
Background
- Right ventricular hypertrophy is a significant condition that can lead to heart failure.
- Understanding the mechanisms behind right ventricular failure is crucial for developing effective treatments.
- Existing methods may not adequately isolate the effects of afterload on the right ventricle.
- This study aims to provide a reliable surgical approach to investigate these effects.
Purpose of Study
- To develop a surgical method for inducing right ventricular hypertrophy and failure in a controlled manner.
- To eliminate confounding factors associated with pulmonary vasodilation.
- To facilitate research into the underlying mechanisms of right ventricular failure.
Methods Used
- Selection of appropriate banding diameter for afterload increase.
- Use of a ligating clip applier to ensure precise banding.
- Preparation of the rat model through anesthesia and surgical incision.
- Dissection of the pectoral muscle to access the thoracic cavity.
Main Results
- The method successfully induced right ventricular hypertrophy in the rat model.
- Afterload increase was reproducible and precise.
- The technique allowed for the study of right ventricular failure without pulmonary vasodilation effects.
- Potential implications for therapeutic approaches to right ventricular failure were identified.
Conclusions
- This surgical method provides a valuable tool for studying right ventricular hypertrophy and failure.
- It enhances understanding of the mechanisms involved in right ventricular dysfunction.
- The findings may inform future therapeutic strategies for treating right ventricular failure.
Frequently Asked Questions
What is right ventricular hypertrophy?
Right ventricular hypertrophy is the thickening of the heart's right ventricle, often due to increased workload.
Why is this method significant?
It allows researchers to study right ventricular failure mechanisms without confounding effects from pulmonary vasodilation.
What animal model is used in this study?
The study uses Wistar rat weanlings for the surgical procedure.
How does the method ensure precision?
The technique involves careful selection of banding diameter and use of a ligating clip applier for accuracy.
What are the implications of this research?
The findings may lead to improved treatments for patients with right ventricular failure.
Is the procedure reversible?
The article does not specify if the procedure is reversible; it focuses on inducing hypertrophy for study purposes.
Executive Industry Relevance
This pulmonary trunk banding model provides a reproducible system for studying pressure overload-induced right ventricular hypertrophy and failure, enabling mechanistic de-risking in cardiovascular target validation. By allowing precise afterload manipulation without pulmonary vasodilation confounders, the model supports predictive confidence in preclinical screening of therapeutic candidates. Its capacity to generate graded disease phenotypes facilitates portfolio triage and translational biomarker alignment in RV failure research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in pressure overload pathways through controlled RV hypertrophy induction.
- Operational Value: Provides biological de-risking via reproducible model of RV failure for target validation studies.
- Scientific Value: Supports predictive confidence by distinguishing compensated hypertrophy from decompensated failure phenotypes.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream compound screening with quantifiable RV functional endpoints.
- Operational Value: Ensures assay standardization through precise banding diameters that yield consistent hypertrophy severity levels.
- Scientific Value: Enables reliable compound evaluation via measurable outputs like RV ejection fraction and cardiomyocyte cross-sectional area.
Translational & Preclinical Research
- Scientific Value: Demonstrates disease relevance through extra-cardiac manifestations in severe banding, mirroring clinical RV failure progression.
- Operational Value: Provides continuity from discovery through preclinical validation with stepwise hemodynamic and structural changes.
- Scientific Value: Facilitates risk-adjusted advancement decisions by correlating banding severity with functional decline.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through preclinical efficacy testing, supporting lead identification in RV failure pathways.
- Discovery Biology: Supports hypothesis testing and pathway clarification in pressure overload-induced RV remodeling.
- Screening: Delivers assay readiness and quantitative outputs including RV pressure, ejection fraction, and fibrosis metrics.
- Analytics: Enables team comparisons through standardized measurements of RV dilation and systolic function.
- Translational Research: Connects to preclinical validation via phenotypic progression from hypertrophy to failure with clinical correlates.
- Enterprise Reuse: Functions as a reusable platform for evaluating multiple therapeutic targets in RV failure mechanisms.
Operational & Enterprise Impact
- Scientific Value: Delivers predictive confidence, target validation, and reduction of mechanistic ambiguity in RV failure pathways.
- Operational Value: Ensures standardization, reproducibility, and scalability across laboratories via clip diameter control.
- Strategic Value: Improves go/no-go decisions, capital efficiency, and reduces late-stage biological risk in cardiovascular programs.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement decisions based on phenotypic severity gradients.
Implementation Considerations
- Requires expertise in microsurgical techniques and cardiovascular anatomy in rodent models.
- Dependent on precision instrumentation including ligating clip appliers and surgical microtools.
- Necessitates cross-team standardization of banding diameter selection for phenotypic consistency.
- Involves adaptation considerations when translating protocols across different rat strains or ages.
- Limited by procedural complexity and survival rates in severe banding cohorts, as noted in source material.
Biopharma FAQs
Why does null hypothesis testing matter for RV hypertrophy validation?
Null hypothesis testing confirms whether observed RV hypertrophy exceeds sham-operated baselines, ensuring phenotypic changes are not due to surgical variability. This statistical rigor supports target validation by distinguishing true pressure overload effects from procedural noise.
How does independent variable isolation fit the cardiovascular discovery pipeline?
Isolating pulmonary trunk banding as the independent variable eliminates confounding effects from pulmonary vasodilation, enabling clean afterload increase attribution. This precision allows mechanistic de-risking of RV failure pathways in early discovery stages.
What quantitative dependent variable measurements enable RV failure assessment?
Measurements including right ventricular ejection fraction, cardiomyocyte cross-sectional area, and tricuspid annular plane systolic excursion provide quantifiable failure metrics. These outputs support preclinical screening by correlating structural changes with functional decline.
Why do replication requirements matter for cross-functional collaboration in RV modeling?
Reproducible banding diameters ensure consistent hypertrophy severity across sites, enabling reliable data sharing between discovery and translational teams. This standardization reduces variability in target validation studies and supports portfolio decision-making.
What statistical analysis capabilities are required before implementing the PTB model?
Teams require capacity for longitudinal analysis of RV pressure, volume, and functional parameters to detect stepwise disease progression. Pre-implementation planning should include power analysis for detecting severity-dependent changes in hypertrophy and failure endpoints.
